{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-166275","form_type":"8-K","ticker":null,"cik":"0001828522","company_name":"eFFECTOR Therapeutics, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.466609+00:00","generated_at":"2026-06-01T02:33:01.908513+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"eFFECTOR Therapeutics to wind down operations, terminate staff, and delist from Nasdaq","bullets":["Company terminated all employees in connection with a planned wind down of operations.","Expects one-time charges of approximately $0.6 million for severance and related costs in Q2 2024.","All seven directors resigned; Stephen Worland (CEO), Michael Byrnes (CFO), and Douglas Warner (CMO) departed.","Craig Jalbert appointed sole director, CEO, President, Treasurer, and Secretary to manage wind down.","Company plans to voluntarily request delisting of common stock and warrants from Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-166275","json":"https://secwatch.observer/filing/0001193125-24-166275.json","markdown":"https://secwatch.observer/filing/0001193125-24-166275.md","text":"https://secwatch.observer/filing/0001193125-24-166275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/d860453d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:33:01.908513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a3f94932f","claim":"Craig R. Jalbert was appointed as sole member of the Board at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"sole member of the Board"}],"fact_type":"executive_change"},{"claim_id":"19628474c3","claim":"Elizabeth P. Bhatt resigned as Director at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"26fc2d1c61","claim":"Michael Byrnes departed as Chief Financial Officer and Secretary at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Financial Officer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"3707894aad","claim":"Stephen T. Worland, Ph.D. resigned as Director at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3798d4adad","claim":"Brian M. Gallagher, Jr., Ph.D. resigned as Director at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7269ce3e33","claim":"Chris Ehrlich resigned as Director at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"99d44314f1","claim":"Craig R. Jalbert was appointed as CEO, President, Treasurer and Secretary at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"CEO, President, Treasurer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"9d3937a59a","claim":"Barbara Klencke, M.D. resigned as Director at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d551ee52d0","claim":"Caroline Loewy resigned as Director at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d5969d338c","claim":"Stephen T. Worland, Ph.D. departed as President and CEO at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"President and CEO"}],"fact_type":"executive_change"},{"claim_id":"e0802ae238","claim":"Kristen Harrington-Smith resigned as Director at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e503364426","claim":"Douglas Warner, M.D. departed as Chief Medical Officer at eFFECTOR Therapeutics, Inc..","evidence_excerpt":"On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}